The Industrial Sensyo Pharmatech project, whose first stone was posed at the end of January, aims to ensure the self-sufficiency of the kingdom and to supply the countries of the continent.
by
A few years ago, the bet seemed crazy; It is now presented as realistic. In 2016, the Moroccan government had imagined creating a national laboratory devoted to the production of vaccines. He had moved closer to the Pasteur Institute of Morocco, had launched a study to see what his chances were to reduce his dependence on the giants of the sector. The project had not been successful. Since then, CIVID-19 has been there and upset the priorities. Not only does the Kérifian kingdom intend to make its vaccines, but it dreams in the African leader of biotechnologies in a five-year horizon.
The first stone of this industrial project was laid on Thursday, January 27 by King Mohammed VI in Benslimane, in the region of Casablanca. The new vaccine manufacturing plant, called Sensyo Pharmatech, intends to have among the top five world platforms. It is ultimately aims to “ensure the self-sufficiency of Morocco in vaccines and position themselves as a key producer of organic products for Africa and the world”, according to Othman Benjelloun, his president, cited by the Moroccan press agency MAP .
At first, the site will not produce Vaccines from A to Z. It will be devoted to the “Fill and Finish” segment, that is, the packaging in vials or syringes of imported products. The first lots of trials are planned for July and production must reach 600 million doses at the end of the year. Later, in the next two to three years, the factory must put, via different technology transfers, to the manufacture of active substances of about twenty vaccines and biotherapeutic products, including three VVID-19 vaccines including the names have not been unveiled yet. Finally, in the long term, the project provides for the creation of a research and development cluster to invent “Made in Morocco” vaccines.
The Kingdom has embarked on the conditioning of the Chinese Vaccine Sinopharm current 2021, after participating in phase 3 testing of the vaccine candidate. To move up and climb in the value chain, it intends to invest “between 400 and 500 million euros, according to the MAP agency. Sums abounded by the Mohammed-VI Fund for the investment and a consortium bringing together the three largest banks in the country. It can also rely on a partnership with the Swedish Pharmaceutical Group Recipharm, which produces the modern vaccine in France.
You have 58.82% of this article to read. The rest is reserved for subscribers.